To print: Select File and then Print from your browser's menu
---------------------------------------------------------------------------------------
Title: New Therapeutic Treatment Approach Improves Survival in Oesophageal Cancer Patients
URL: http://www.pslgroup.com/dg/22E402.htm
Doctor's Guide
October 6, 2008

ORLANDO, Fla -- October 6, 2008 -- A new therapeutic treatment, when delivered endoscopically and used in combination with chemotherapy and radiation therapy, improved survival rates in patients with locally advanced oesophageal cancer, according to a study presented at the American College of Gastroenterology 73rd Annual Scientific Meeting in Orlando, Florida.

Kenneth Chang, MD, University of California Irvine Medical Center, Irvine, California, and colleagues conducted a phase 2 multicentre study on the safety and long-term efficacy of an injection of an anti-tumour agent (TNFerade), in 24 patients with locally advanced oesophageal cancer.

Patients received standard care chemotherapy and radiation. In addition, the patients received the agent through a standard endoscope or endoscopic ultrasound that guided the injection directly into the oesophageal tumour.

The agent was administered once a week for a total of 5 treatments. Surgery was performed 5 to 11 weeks after completion of therapy. Researchers monitored the effects of this combined therapy by observing the side effects, tumour response, and overall survival.

Researchers found most tumours were of the adenocarcinoma type. These tumours were locally advanced but still potential candidates for surgery.

The agent in combination with chemoradiation in this group of patients resulted in a median survival of 48.4 months, in contrast to previously published trials showing a median survival of 9.7 to 34 months. At one particular dose all 4 of the patients were alive without any recurrence at 48 months. Three of these patients had tumour resections, which showed no residual cancer cells in the surgical specimens.

"This new treatment, in combination with chemoradiation in this group of patients, represents an encouraging increase in survival relative to historical controls, and therefore, warrants additional evaluation," said Dr. Chang.

"[This agent] is a promising treatment that represents a new paradigm in oesophageal cancer treatment, with the gastroenterologist administering the local anti-tumour agent through a scope."


SOURCE: American College of Gastroenterology

---------------------------------------------------------------------------------------------
Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.
---------------------------------------------------------------------------------------------
This news story was printed from *Doctor's Guide to the Internet*
located at http://www.docguide.com
---------------------------------------------------------------------------------------

Return to News Story Page

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.
All contents Copyright (c) 1998 P\S\L Consulting Group Inc.
All rights reserved.